Last updated: Jan 19, 2021

COVID-19 vaccine development tracker

vizient.

Manufacturer	Partner	Current phase	Type/ technology	Initial doses ordered (US)	Dose capacity (global)	Notes
PFIZER	BIONTECH, ACUITAS THERAPEUTICS	PHASE III	mRNA	100 MILLION	800 MILLION	**BNT162b2.** Approved with an EUA by the FDA. Storage requirement of current vaccine candidate(s) requires frozen temperatures (-70 C). Must ship frozen and be stored frozen. Physical shipment of vaccine handled by Pfizer. 2ml vial. 5 doses per vial. Will require reconstitution with diluent. Will require 2 doses 21 days apart. All doses in vial must be administered within 6 hours of reconstitution.
MODERNA		PHASE III	mRNA	100 MILLION	600 MILLION	**mRNA-1273.** Approved with an EUA by the FDA.. **Vaccine stable at refrigerated temperatures of 2 to 8 degrees C for 30 days.** Physical shipment of vaccine will be handled by McKesson. 5 ml vial. 10 doses per vial. All doses in vial must be administered within 6 hours after vial puncture. Will require 2 doses 28 days apart
J&J	Emergent Biosolutions	PHASE III	ADENOVIRUS	100 MILLION	1.2 BILLION	**AD26.COV2-S.** Expect a vaccine to be available in Feb 2021 pending FDA emergency use authorization (EUA). Currently in Phase III. Study [ENSEMBLE trial] includes 45,000 patients worldwide which includes 180 worldwide locations in the US as well as 8 other countries (i.e. South Africa, Brazil, Chile). Phase III trial will compare efficacy of 1 single dose vs placebo. Will also study the effect in sub-populations. Storage requirements of current candidate(s) is refrigeration only. Will require 1 dose only. 0.5ml per dose. 5 doses per vial Company has pledged to provide vaccine on an "at cost/no-profit" basis.
ASTRAZENECA	OXFORD	PHASE III	ADENOVIRUS	300 MILLION	1 BILLION	**AZD-1222.** Currently approved in the UK. Filed application 1/12/21 in EU for approval. Expect a vaccine to be available in the USA in Feb 2021 pending FDA emergency use authorization (EUA). Current candidate can be stored at refrigerated temperatures for up to 3 months. Will require 2 doses approx 28 days apart. UK studying 2 doses up to 12 weeks apart. 5ml liquid vial. 10 doses per vial. Company has pledged to provide vaccine on an "at cost/no-profit" basis.
NOVAVAX	Par/Endo	Phase III	Rec. Protein Nanoparticle	100 MILLION		**NVX-CoV2373.** Phase I results published in NEJM 9/2/20. Phase II trial conducted in South Africa. Entered into Phase III clinical trial in UK in late Sept. 2020. Enrollment of 15,000 patients with a goal of 25% of those patients being over the age of 65. Expect to reach full enrollment by end of Nov 2020. Earliest data release expected in in Q1 of 2021. US Phase III trial began late-December 2020.
MERCK	RIDGEBACK BIO	PHASE II/III				**MK-4482** (formerly known as EIDD-2801). Molnupiravir. Oral antiviral agent being developed to treat COVID-19 in patients. 1st patient dosed in Phase2/3 study 10/19/20
SANOFI PASTEUR	GlaxoSmithKline	PHASE II	Recombinant Technology + Adjuvant	100 MILLION	1 BILLION	**SCB-2019.** Launched Phase 1/2 in early Sept 2020 randomized, placebo controlled with 440 participants. Phase 2b to begin in Feb 2021. Currently plans to study the efficacy of a single dose and a 2-dose series. Expect a viable vaccine for approval by Q2 of 2021 under an Emergency Use Authorization (EUA) Storage requirements of current candidate(s) is refrigeration only.
CUREVAC	BAYER	PHASE IIb	mRNA			**CVnCoV.** The phase 2b study will randomize 4,00 subjects across 2 age cohorts. 2 dose series 4 weeks apart.
SANOFI PASTEUR	Translate Bio	Phase I/II	mRNA		90 MILLION	**MRT5500.** Phase I/II trials to begin in Q1 2021.Expected production of 90 million doses
MERCK	IAVI, THEMIS	PHASE I	Vesicular Stomatitis			**V590, V591** Working on 2 different potential candidates. Expected delivery in late 2021.
• Last updated 1/19/21						
For inquiries, please contact pharmacyquestions@vizientinc.com						